Published in Toxins (Basel) on June 11, 2012
A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect Immun (2013) 1.06
Disease-enhancing antibodies improve the efficacy of bacterial toxin-neutralizing antibodies. Cell Host Microbe (2013) 0.90
Antibodies for treatment of Clostridium difficile infection. Clin Vaccine Immunol (2014) 0.87
Role of Fc in antibody-mediated protection from ricin toxin. Toxins (Basel) (2014) 0.83
Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays. Infect Immun (2013) 0.83
The molecular mechanism of Shiga toxin Stx2e neutralization by a single-domain antibody targeting the cell receptor-binding domain. J Biol Chem (2014) 0.80
Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs. Toxins (Basel) (2015) 0.79
Molecular characterization of Clostridium botulinum isolates from foodborne outbreaks in Thailand, 2010. PLoS One (2014) 0.78
Prevention and treatment of Clostridium perfringens epsilon toxin intoxication in mice with a neutralizing monoclonal antibody (c4D7) produced in Nicotiana benthamiana. Toxicon (2014) 0.78
Preparation and evaluation of human-murine chimeric antibody against protective antigen of Bacillus anthracis. Int J Mol Sci (2014) 0.77
Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations. PLoS One (2014) 0.76
Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum Apical Membrane Antigen 1. Sci Rep (2016) 0.75
Bacterial Toxins-Staphylococcal Enterotoxin B. Microbiol Spectr (2013) 0.75
Antibodies and superantibodies in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol (2016) 0.75
Preparation and identification of monoclonal antibodies against ω-conotoxin MVIIA. Monoclon Antib Immunodiagn Immunother (2014) 0.75
Immunization with non-toxic variants of Shiga toxin type 2 (Stx2) generates high titers of protective antibodies. Dokl Biochem Biophys (2015) 0.75
Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 83.56
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics (1998) 49.00
Of mice and not men: differences between mouse and human immunology. J Immunol (2004) 10.61
Gut flora in health and disease. Lancet (2003) 9.85
Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect Immun (1985) 5.04
THE PROTECTIVE ACTION OF TYPE I ANTIPNEUMOCOCCUS SERUM IN MICE : I. THE QUANTITATIVE ASPECTS OF THE MOUSE PROTECTION TEST. J Exp Med (1935) 4.90
Cross-reacting antibodies enhance dengue virus infection in humans. Science (2010) 4.63
Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov (2010) 4.47
Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov (2009) 3.66
Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science (1988) 3.44
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16
Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol (2009) 3.05
Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies. Infect Immun (1988) 2.99
Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol Aspects Med (2009) 2.93
Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol (2002) 2.77
Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay. J Clin Microbiol (1988) 2.76
Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun (1988) 2.63
Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections. Infect Immun (1984) 2.59
Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology (1996) 2.16
Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies. Infect Immun (1989) 2.12
Antibody-based therapeutics to watch in 2011. MAbs (2011) 2.00
mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc Natl Acad Sci U S A (2004) 1.83
Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther (2007) 1.83
Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect Immun (1990) 1.78
Immunological characteristics associated with the protective efficacy of antibodies to ricin. J Immunol (2004) 1.76
Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol (2008) 1.74
A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin. Infect Immun (2009) 1.68
Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines. Nature (1979) 1.65
Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect Immun (2004) 1.64
Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo. Hybridoma (1994) 1.62
Effect of monoclonal antibody to pertussis toxin on toxin activity. Infect Immun (1987) 1.61
Folding domains within the ricin toxin A subunit as targets of protective antibodies. Vaccine (2010) 1.60
A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med (2010) 1.58
Advances in saponin-based adjuvants. Vaccine (2009) 1.58
Isotype selection in antibody engineering. Nat Biotechnol (2007) 1.57
Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun (1997) 1.56
Infectivity-enhancing antibodies to Ebola virus glycoprotein. J Virol (2001) 1.52
Characterization of a novel high-affinity monoclonal immunoglobulin G antibody against the ricin B subunit. Infect Immun (2006) 1.50
Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun (2002) 1.49
Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect Immun (2004) 1.47
Monoclonal antibody-based therapies for microbial diseases. Vaccine (2009) 1.47
Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J Immune Based Ther Vaccines (2004) 1.46
Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect Immun (1984) 1.45
Monoclonal antibodies to pertussis toxin: utilization as probes of toxin function. Hybridoma (1989) 1.43
Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother (1994) 1.41
Interaction of monoclonal antibodies with pertussis toxin and its subunits. Infect Immun (1984) 1.40
Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun (2007) 1.40
Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J Infect Dis (2006) 1.40
A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect Immun (2006) 1.38
Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun (2006) 1.38
Production and characterisation of monoclonal antibodies to Verotoxins 1 and 2 from Escherichia coli of serotype O 157:H7. J Med Microbiol (1989) 1.38
Protective activities in mice of monoclonal antibodies against pertussis toxin. Infect Immun (1990) 1.37
In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect Immun (2007) 1.33
Modulation of Bordetella pertussis infection with monoclonal antibodies to pertussis toxin. J Infect Dis (1991) 1.32
Immunoglobulin A antibodies against ricin A and B subunits protect epithelial cells from ricin intoxication. Infect Immun (2006) 1.32
The use of monoclonal antibodies to analyze the structure of Clostridium botulinum type E derivative toxin. Infect Immun (1986) 1.30
Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect Immun (2006) 1.28
High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother (2007) 1.27
Neutralising antibodies against ricin toxin. PLoS One (2011) 1.26
Production and characterization of protective human antibodies against Shiga toxin 1. Infect Immun (2002) 1.23
Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol (1994) 1.22
Protective immunity to ricin toxin conferred by antibodies against the toxin's binding subunit (RTB). Vaccine (2011) 1.22
High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect Immun (2001) 1.22
Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun (2009) 1.22
Isolation and characterization of monoclonal antibodies to Shiga toxin. Infect Immun (1983) 1.21
Four different monoclonal antibodies against type C1 toxin of Clostridium botulinum. Infect Immun (1982) 1.21
Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model. Hum Antibodies (2003) 1.20
An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect Immun (2005) 1.20
Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol (2009) 1.19
Pertussis toxin analog with reduced enzymatic and biological activities is a protective immunogen. Infect Immun (1990) 1.19
Epitope mapping of monoclonal antibodies against Bordetella pertussis adenylate cyclase toxin. Infect Immun (1999) 1.19
Anti-infective monoclonal antibodies: perils and promise of development. Nat Rev Drug Discov (2006) 1.18
Monoclonal antibodies defining functional sites on the toxin superantigen staphylococcal enterotoxin B. J Exp Med (1994) 1.17
Generation, characterization, and epitope mapping of neutralizing and protective monoclonal antibodies against staphylococcal enterotoxin B-induced lethal shock. J Biol Chem (2011) 1.17
Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother (2005) 1.17
Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS One (2008) 1.11
Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol Med Microbiol (2006) 1.10
Identification and characterization of a monoclonal antibody recognizing a galactose-binding domain of the toxin ricin. J Immunol (1987) 1.09
Analysis of antigenicity of Clostridium botulinum type C1 and D toxins by polyclonal and monoclonal antibodies. Infect Immun (1984) 1.09
Identification of a novel functional domain of ricin responsible for its potent toxicity. J Biol Chem (2011) 1.08
Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies. Infect Immun (1991) 1.08
Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies. J Biol Chem (2009) 1.06
Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin. J Immunol (1993) 1.06
Monoclonal antibodies that define neutralizing epitopes of pertussis toxin: conformational dependence and epitope mapping. Infect Immun (1989) 1.05
Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen. Infect Immun (2009) 1.05
Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies. Biochem Biophys Res Commun (1994) 1.04
Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B. PLoS One (2010) 1.03
Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology. N Biotechnol (2011) 1.03
Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect Immun (2008) 1.02
Raxibacumab. MAbs (2009) 1.02
Antibodies for biodefense. MAbs (2011) 1.02
Monoclonal antibodies against ricin: effects on toxin function. Hybridoma (1986) 1.02
Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B. Toxicon (2004) 1.01
Monoclonal antibody prophylaxis against the in vivo toxicity of ricin in mice. Immunol Invest (1993) 1.00
Potent neutralization of staphylococcal enterotoxin B by synergistic action of chimeric antibodies. Infect Immun (2010) 0.99
Production and characterization of monoclonal antibodies with therapeutic potential against Shiga toxin. J Clin Lab Immunol (1990) 0.99
Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin type A. Appl Environ Microbiol (2001) 0.98
Monoclonal antibody for the detection of Clostridium botulinum type A toxin. Mol Cell Probes (1987) 0.98
Monoclonal antibody to Shiga toxin 2 which blocks receptor binding and neutralizes cytotoxicity. Infect Immun (1999) 0.97
Misconduct accounts for the majority of retracted scientific publications. Proc Natl Acad Sci U S A (2012) 5.89
Causes for the persistence of impact factor mania. MBio (2014) 3.77
Why has the number of scientific retractions increased? PLoS One (2013) 3.59
Retracted science and the retraction index. Infect Immun (2011) 3.35
The contribution of melanin to microbial pathogenesis. Cell Microbiol (2003) 3.12
Cryptococcosis. Infect Dis Clin North Am (2002) 3.01
Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr Biol (2006) 2.92
Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci U S A (2002) 2.68
Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot Cell (2006) 2.55
Public health and biosecurity. Adaptations of avian flu virus are a cause for concern. Science (2012) 2.52
Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence. Eukaryot Cell (2007) 2.42
NIH peer review reform--change we need, or lipstick on a pig? Infect Immun (2009) 2.21
Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother (2006) 2.12
The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J Biol Chem (2005) 2.07
Fungal cell gigantism during mammalian infection. PLoS Pathog (2010) 2.04
Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun (2003) 2.00
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2). Infect Immun (2003) 1.89
Reforming science: methodological and cultural reforms. Infect Immun (2011) 1.85
The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans. Microbes Infect (2003) 1.84
CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity (2002) 1.83
More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol (2003) 1.81
Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice. J Clin Invest (2011) 1.80
An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov (2010) 1.78
Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci U S A (2013) 1.76
Vesicular transport in Histoplasma capsulatum: an effective mechanism for trans-cell wall transfer of proteins and lipids in ascomycetes. Cell Microbiol (2008) 1.73
Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci U S A (2003) 1.71
Ionizing radiation changes the electronic properties of melanin and enhances the growth of melanized fungi. PLoS One (2007) 1.70
Lost in translation--basic science in the era of translational research. Infect Immun (2009) 1.70
The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem (2007) 1.67
Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryot Cell (2004) 1.64
The presence of female conveners correlates with a higher proportion of female speakers at scientific symposia. MBio (2014) 1.63
Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot Cell (2007) 1.63
Bacillus anthracis produces membrane-derived vesicles containing biologically active toxins. Proc Natl Acad Sci U S A (2010) 1.62
Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother (2005) 1.61
An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J Immunol (2005) 1.61
Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest (2003) 1.60
Important science--it's all about the SPIN. Infect Immun (2009) 1.59
A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med (2010) 1.58
Ionizing radiation: how fungi cope, adapt, and exploit with the help of melanin. Curr Opin Microbiol (2008) 1.58
Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother (2002) 1.57
Global warming will bring new fungal diseases for mammals. MBio (2010) 1.56
Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog (2007) 1.55
Policy: Adaptations of avian flu virus are a cause for concern. Nature (2012) 1.54
Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online (2004) 1.52
Vertebrate endothermy restricts most fungi as potential pathogens. J Infect Dis (2009) 1.51
Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol (2007) 1.51
Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol (2008) 1.50
Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes. J Nucl Med (2004) 1.47
Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection. J Infect Dis (2006) 1.47
Monoclonal antibody-based therapies for microbial diseases. Vaccine (2009) 1.47
Sec6-dependent sorting of fungal extracellular exosomes and laccase of Cryptococcus neoformans. Mol Microbiol (2008) 1.46
Synthesis and assembly of fungal melanin. Appl Microbiol Biotechnol (2011) 1.45
The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol (2003) 1.45
Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot Cell (2007) 1.45
Cryptococcus neoformans virulence is enhanced after growth in the genetically malleable host Dictyostelium discoideum. Infect Immun (2003) 1.44
The effect of L-DOPA on Cryptococcus neoformans growth and gene expression. Virulence (2011) 1.42
Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother (2006) 1.42
Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun (2005) 1.42
Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions. Infect Immun (2010) 1.40
Microstructure of cell wall-associated melanin in the human pathogenic fungus Cryptococcus neoformans. Biochemistry (2005) 1.40
Experimental murine cryptococcal infection results in contamination of bedding with Cryptococcus neoformans. Contemp Top Lab Anim Sci (2003) 1.40
Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans. Eukaryot Cell (2007) 1.39
Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med (2006) 1.38
A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect Immun (2006) 1.38
The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol (2006) 1.37
Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol (2008) 1.36
Binding of the wheat germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan. Eukaryot Cell (2007) 1.36
The radioprotective properties of fungal melanin are a function of its chemical composition, stable radical presence and spatial arrangement. Pigment Cell Melanoma Res (2008) 1.36
Reforming science: structural reforms. Infect Immun (2011) 1.36
The capsular dynamics of Cryptococcus neoformans. Trends Microbiol (2006) 1.35
Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun (2005) 1.33
The immunoglobulin constant region contributes to affinity and specificity. Trends Immunol (2008) 1.32
Histoplasma capsulatum synthesizes melanin-like pigments in vitro and during mammalian infection. Infect Immun (2002) 1.31
Vesicle-associated melanization in Cryptococcus neoformans. Microbiology (2009) 1.31
Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis. Eur J Immunol (2003) 1.30
The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect Immun (2007) 1.30
Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J Immunol (2002) 1.30
Mechanistic science. Infect Immun (2009) 1.29
Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection. PLoS One (2011) 1.29
Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe (2013) 1.26
Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc Natl Acad Sci U S A (2004) 1.26
Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect Immun (2002) 1.24
Characterization of yeast extracellular vesicles: evidence for the participation of different pathways of cellular traffic in vesicle biogenesis. PLoS One (2010) 1.24
Males are overrepresented among life science researchers committing scientific misconduct. MBio (2013) 1.22
Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8. Cell Microbiol (2006) 1.22
Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule. Eukaryot Cell (2006) 1.21
Estimating the relative contributions of virulence factors for pathogenic microbes. Infect Immun (2006) 1.21
Quorum sensing in fungi--a review. Med Mycol (2012) 1.21
Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J Immunol (2005) 1.20
Synthesis of melanin-like pigments by Sporothrix schenckii in vitro and during mammalian infection. Infect Immun (2003) 1.19
Bioterrorism: lessons learned since the anthrax mailings. MBio (2011) 1.19
Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules. Proc Natl Acad Sci U S A (2009) 1.19
Cryptococcus neoformans biofilm formation depends on surface support and carbon source and reduces fungal cell susceptibility to heat, cold, and UV light. Appl Environ Microbiol (2007) 1.18
Galactoxylomannan does not exhibit cross-reactivity in the platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol (2007) 1.17
Treating cancer as an infectious disease--viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology. PLoS One (2007) 1.17
The polysaccharide capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation. J Leukoc Biol (2003) 1.17
Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: a role for nitric oxide. J Immunol (2002) 1.16
Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J Clin Invest (2010) 1.16
Nonlytic exocytosis of Cryptococcus neoformans from macrophages occurs in vivo and is influenced by phagosomal pH. MBio (2011) 1.15